Guinness Asset Management LTD Buys New Stake in Jazz Pharmaceuticals PLC $JAZZ

Guinness Asset Management LTD purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 3,300 shares of the specialty pharmaceutical company’s stock, valued at approximately $426,000.

Other institutional investors also recently bought and sold shares of the company. LSV Asset Management raised its position in shares of Jazz Pharmaceuticals by 3.6% during the 2nd quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock worth $271,003,000 after acquiring an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. increased its stake in Jazz Pharmaceuticals by 11.4% in the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after purchasing an additional 191,637 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Jazz Pharmaceuticals by 3.6% during the second quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock worth $182,664,000 after purchasing an additional 59,252 shares in the last quarter. Vestal Point Capital LP purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $127,344,000. Finally, Geode Capital Management LLC lifted its position in shares of Jazz Pharmaceuticals by 1.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock worth $124,366,000 after buying an additional 16,757 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Rick E. Winningham sold 5,500 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total value of $994,730.00. Following the completion of the sale, the director owned 8,893 shares in the company, valued at approximately $1,608,387.98. This trade represents a 38.21% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total transaction of $379,363.38. Following the completion of the sale, the senior vice president directly owned 19,508 shares in the company, valued at approximately $3,306,801.08. The trade was a 10.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 123,791 shares of company stock valued at $21,991,850. Corporate insiders own 4.30% of the company’s stock.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $20.06 (from $19.95) and bumped several 2026–2027 quarterly estimates (Q4 2027 to $5.50, Q3 2027 to $5.70, Q2 2027 to $5.04, Q4 2026 to $5.00). Those upward revisions signal improving medium-term profit expectations from a well-known independent research shop, which can support higher valuation expectations. Zacks Research Issues Positive Outlook for JAZZ Earnings
• Neutral Sentiment: The estimate changes are mostly small in magnitude (cent-to-tenth-of-dollar moves), suggesting incremental rather than transformational upside; investors may wait for company-reported results to confirm the trend before materially re-pricing the stock.
• Negative Sentiment: Zacks trimmed a few nearer-term quarter estimates (Q2 2026 to $4.88, Q3 2026 to $5.25, Q4 2025 to $5.15). Even modest downgrades to near-term prints can prompt short-term selling or raise caution among traders focused on the next reported quarter.
• Negative Sentiment: Despite the mostly positive medium-term lift, the stock traded lower — likely reflecting profit-taking/technical pressure after a recent run toward its 52-week high and the 50-day moving average acting as resistance (50‑day MA $168.36 vs. current below that). Lower-than-average intraday volume also suggests limited buying conviction.

Analysts Set New Price Targets

Several equities research analysts recently commented on JAZZ shares. Bank of America lifted their price target on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. UBS Group reaffirmed a “neutral” rating and set a $188.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Needham & Company LLC raised their price target on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, JPMorgan Chase & Co. cut their price target on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research report on Monday, October 27th. Fourteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $205.67.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $163.15 on Friday. The stock has a market capitalization of $9.91 billion, a PE ratio of -26.88, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The stock’s 50-day moving average price is $168.08 and its 200 day moving average price is $144.95. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.